THE FDA has approved a worldfirst
“cancer vaccine”, Provenge, for
the treatment of prostate cancer.
Provenge does not actually
prevent prostate cancer, but rather
it may prolong the life expectancy
of sufferers.
Treatment involves a series of
three Provenge injections, which
are custom made using the
patient’s own cells to train the
immune system to recognise and
kill malignant cancer cells.
Trials of the drug found that
compared to the placebo, 32% of
patients treated with Provenge were
alive after three years.The above article was sent to subscribers in Pharmacy Daily's issue from 03 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 May 10
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.